ADMA Biologics, Inc. (ADMA)

US — Healthcare Sector
Peers: ATRA  FATE  SANA  CRBU  RCUS  TFFP  INMB  ANEB  ABCM  ANTX  ETNB  MDGL  PLRX  ACLX  STOK  PLX  CDTX  AKBA  XFOR  MCRB  VXRT  IBIO  TNXP  BCRX 

Automate Your Wheel Strategy on ADMA

With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ADMA
  • Rev/Share 1.932
  • Book/Share 1.5705
  • PB 12.6332
  • Debt/Equity 0.2196
  • CurrentRatio 6.5762
  • ROIC 0.4874

 

  • MktCap 4736482560.0
  • FreeCF/Share 0.3813
  • PFCF 52.2462
  • PE 22.8149
  • Debt/Assets 0.1606
  • DivYield 0
  • ROE 0.7239

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 1
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
ADMA, GRFS
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

Read More
image for news ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
ADMA
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral

ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repurchase program.

Read More
image for news ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
ADMA
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.

Read More
image for news ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
ADMA
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025. At this time, all participants are in a listen-only mode.

Read More
image for news ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates
ADMA
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.

Read More
image for news Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates
3 Mid-Cap Medical Stocks Outperforming the Market
ADMA, PEN, TMDX
Published: May 06, 2025 by: MarketBeat
Sentiment: Positive

While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.

Read More
image for news 3 Mid-Cap Medical Stocks Outperforming the Market
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
ADMA, DGX, LMB
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Read More
image for news Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
ADMA
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.

Read More
image for news Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?
ADMA
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.

Read More
image for news Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know
ADMA
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
ADMA
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Read More
image for news Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date
ADMA, FCFS, LRN, LTH, NFG
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Five mid-cap high-flying stocks to buy are: ADMA, FCFS, LRN, LTH, NFG.

Read More
image for news These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
ADMA
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

RAMSEY, N.J. and BOCA RATON, Fla.

Read More
image for news ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
ADMA
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity

Read More
image for news ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
ADMA
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
ADMA
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Read More
image for news Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
ADMA
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Read More
image for news Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
ADMA, BMRN, FOLD, GILD, KRYS
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.

Read More
image for news 5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
ADMA
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
ADMA
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive

ADMA Biologics Inc (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Read More
image for news Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
ADMA
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
ADMA
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Read More
image for news Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Will ADMA Biologics Stock Continue Its Momentum in 2025?
ADMA
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive

ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.

Read More
image for news Will ADMA Biologics Stock Continue Its Momentum in 2025?
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views?
ADMA
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views?
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%
ADMA
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
ADMA
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

Block & Leviton is investigating ADMA Biologics for potential securities fraud. Investors who lost money in ADMA should contact the firm to learn more.

Read More
image for news BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET.

Read More
image for news ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ADMA
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

RAMSEY, N.J. and BOCA RATON, Fla.

Read More
image for news ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
ADMA
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative

Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session.

Read More
image for news Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Pharma Stock Poised to Bounce Off Support
ADMA
Published: February 12, 2025 by: Schaeffers Research
Sentiment: Positive

Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.

Read More
image for news Pharma Stock Poised to Bounce Off Support

About ADMA Biologics, Inc. (ADMA)

  • IPO Date 2013-10-17
  • Website https://www.admabiologics.com
  • Industry Biotechnology
  • CEO Mr. Adam S. Grossman
  • Employees 685

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.